Issue link: https://www.e-digitaleditions.com/i/977310
Tablets & Capsules May 2018 41 3. Schwabe, U. & Paffrath, D., Hrsg. (2007). Arzneiveror- dnungs-Report 2007. Aktuelle Daten, Kosten, Trends und Kommentare. Heidelberg: Springer Medizin Verlag. 4. Mattar, R. et al. (2012). Lactose intolerance: diagnosis, genetic, and clinical factors. Clinical and Experimental Gastroenterology, 2012:5 113- 121. 5. Deng, Y. et al. (2015). Lactose Intolerance in Adults: Biological Mechanism and D i e t a r y M a n a g e m e n t . Nutrients, 2015, 7, 8820-8835. 6. Emdex is a registered trademark of JRS Pharma, Rosenberg, Germany. 7. Reactine is a registered trade- m a r k o f M c N e i l C o n s u m e r Healthcare, Fort Washington, PA. 8. Opadry Y-1-7000 is a registered trademark of Colorcon, Harleysville, PA. Hanna Bogner is applications manager and Gernot Warnke, PhD, is global head of product development and technical ser- vices at JRS Pharma (845 878 8300, www.jrspharma.com). Figure 2 Dissolution profile of lactose- and dextrates-based tablets compared to reference product Dissolution (%) 120 100 80 60 40 20 0 0 10 20 30 40 Time (min) Reactine Lactose formulation Dextrates formulation Table 4 Tablet characteristics of lactose- and dextrates-based tablets compared to reference product (Reactine) Parameter Reactine Lactose-based formulation Dextrates-based formulation Crushing strength (N) 79 76 80 Compaction force (kN) – 5.75 4.15 Disintegration time < 3 min 3 min < 3 min Tablet weight (mg) 120 128 126 Tablet height (mm) 3.2 3.4 3.5 www.tabletscapsules.com J u n e 2 0 1 8 Fo r m u l a t i o n Pr o d u c t i o n Pa c k a g i n g F P P TABLETS & CAPSULES Sourcebook Sourcebook Solid Dosage The Solid Dosage Sourcebook is coming in June. Don't miss it. Subscribe now.